GSK3335103, an oral αvβ6 integrin inhibitor, suppresses TGF-β activation in human IPF lung tissues and mouse models of bleomycin-induced pulmonary fibrosis. This evidence concerns the gene TGFB1 and pulmonary fibrosis.